Jonathan C Javitt Net Worth

The estimated Net Worth of Jonathan C Javitt is at least $279 mil dollars as of 27 August 2008. Jonathan Javitt owns over 40,000 units of Brainstorm Cell Therapeutics stock worth over $268,800 and over the last 17 years Jonathan sold BCLI stock worth over $10,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jonathan Javitt BCLI stock SEC Form 4 insiders trading

Jonathan has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2008, according to the Form 4 filled with the SEC. Most recently Jonathan sold 40,000 units of BCLI stock worth $10,000 on 27 August 2008.

The largest trade Jonathan's ever made was selling 40,000 units of Brainstorm Cell Therapeutics stock on 27 August 2008 worth over $10,000. On average, Jonathan trades about 13,333 units every 0 days since 2007. As of 27 August 2008 Jonathan still owns at least 960,000 units of Brainstorm Cell Therapeutics stock.

You can see the complete history of Jonathan Javitt stock trades at the bottom of the page.

What's Jonathan Javitt's mailing address?

Jonathan's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 110 EAST 59TH STREET, NEW YORK, NY, 10022.

Insiders trading at Brainstorm Cell Therapeutics

Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, eInternational Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.

What does Brainstorm Cell Therapeutics do?

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr

Complete history of Jonathan Javitt stock trades at Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics executives and stock owners

Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include:

• Chaim Lebovits,
  Chief Exec. Officer
• Chaim Lebovits,
  Chief Executive Officer
• Ralph Kern,
  President, Chief Medical Officer
• Dr. Ralph Z. Kern,
  Pres & Chief Medical Officer
• Dr. Stacy R. Lindborg Ph.D.,
  Exec. VP & Chief Devel. Officer
• Preetam Shah,
  Chief Financial Officer, Executive Vice President, Treasurer
• Irit Arbel,
  Vice Chairman of the Board
• Malcolm Taub,
  Independent Director
• Uri Yablonka,
  Executive Vice President, Chief Business Officer, Director
• June Almenoff,
  Independent Director
• Anthony Polverino,
  Independent Director
• Arturo Araya,
  Chief Commercial Officer
• Uri Yablonka,
  Exec. VP, Chief Bus. Officer, Sec. & Director
• Dr. Irit Arbel DSc, Ph.D.,
  Co-Founder & Independent Vice Chair of the Board
• Dr. Irit Arbel Ph.D., DSc,
  Co-Founder & Independent Vice Chair of the Board
• Sankesh Abbhi,
  Director
• Anthony Waclawski,
  Executive Vice President - Global Head of Regulatory Affairs
• Stacy Lindborg,
  Executive Vice President Head of Global Clinical Research
• David Setboun,
  Chief Operating Officer, Executive Vice President
• Jacob Frenkel,
  Chairman of the Board
• Antal Pearl-Lendner,
  VP & Chief Legal Counsel
• Alla Patlis CPA, M.B.A.,
  Controller & Interim CFO
• William K. White,
  Sr. VP & Head of Market Access and Pricing
• Dr. Daniel Offen,
  Chief Scientific Advisor
• Dr. Yael Gothelf,
  VP of Scientific & Regulatory Affairs
• Dr. David Setboun M.B.A., Pharm.D.,
  Exec. VP & COO
• Dr. Preetam Shah M.B.A., Ph.D.,
  Exec. VP, CFO & Treasurer
• Mordechai Friedman,
  Director
• International Holdings Ltd....,
  
• Alon Pinkas,
  Director
• Robert G L Shorr,
  Director
• Yoram Bibring,
  Chief Financial Officer
• Chen Schor,
  Director
• Eyal Rubin,
  CFO and Treasurer
• Nir Naor,
  Director
• Alla Patlis,
  See Remarks
• Anthony S. Fiorino,
  Chief Executive Officer
• Liat Sossover,
  Chief Financial Officer
• Avi Israeli,
  Director
• Adrian Harel,
  Acting Chief Executive Officer
• Corp. Accbt,
  10% owner
• Aviv University Economic Co...,
  10% owner
• Aviv University Tel,
  10% owner
• Abraham Efrati,
  Chief Executive Officer
• David Stolick,
  Chief Financial Officer
• At Tel Aviv University Ltd ...,
  10% owner
• Jonathan C Javitt,
  Director
• Beck Yaffa,
  President and CEO
• Moshe Lion,
  Director
• Michael D Greenfield,
  Director
• Yoram Drucker,
  Chief Operating Officer
• Mike Frankenberger,
  
• Kirk Taylor,
  Chief Medical Officer
• Hartoun Hartounian,
  EVP, Chief Operating Officer
• Ibrahim B. Dagher,
  Chief Medical Officer